Recruiting

Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status

ClinicalTrials.gov IDNCT07350928

PhasePHASE3

Enrollment394

SponsorTianjin Medical University Cancer Institute and Hospital

Age20 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Breast Cancer

About this study

This clinical trial aims to evaluate the efficacy and safety of Dexmedetomidine Hydrochloride Nasal Spray for conscious sedation and anxiety relief during breast-conserving surgery. The main questions it aims to answer are: Does Dexmedetomidine Hydrochloride Nasal Spray effectively provide intraoperative sedation and improve postoperative awakening time? What changes in vital signs or postoperative complications do participants experience when using this medication? Researchers will compare Dexmedetomidine Hydrochloride Nasal Spray to a placebo (saline nasal spray) to determine its efficacy in breast-conserving surgery. Participants will: Receive preoperative administration of either Dexmedetomidine Hydrochloride Nasal Spray or the placebo nasal spray; Undergo regular intraoperative and postoperative assessments, including sedation scores, awakening time, and pain scores; Provide satisfaction feedback and be monitored for changes in vital signs and complications.

Interventions

Drug: Induction of anesthesia with dexmedetomidine nasal spray prior to surgery — Induction of anesthesia with dexmedetomidine nasal spray prior to surgery
Drug: Induction of anesthesia with placebo spray prior to surgery — Induction of anesthesia with placebo spray prior to surgery

Primary outcomes

Observer's Assessment of Alterness/Sedation and Numerical rating scale (From enrollment to the end of the first postoperative day)
Hospital Anxiety and Depression Scale (HADS) (From enrollment to the end of the first postoperative day)

Eligibility information

Inclusion Criteria: * Sign the informed consent for * The patients included in the study were women aged between 20 and 70. * ASA (American Society of Anesthesiologists) I-II. * BMI:18-26 Kg/m ² Exclusion Criteria: * Subjects deemed unsuitable for nasal spray administration by the researchers (such as those with severe rhinitis, nasal deformities, etc.); * Severe bradycardia (HR \< 50 beats/min), history of cardiac conduction block; * History of upper respiratory tract infection; * History of asthma; * History of allergy to DEX or local anesthetics; * Subjects who have taken anti-anxiety medication before the operation; * Subjects with a history of ischemic stroke or transient ischemic attack; * Subjects with poorly controlled blood pressure despite medication; * Subjects with a history of mental illness, cognitive impairment, or epilepsy; * Subjects with a history of pregnancy; * Subjects who have been taking sedatives or analgesics for a long time; * Subjects with a history of liver or kidney function impairment; * Subjects with a history of drug or alcohol abuse; * Other situations that the reviewers consider to be disqualifying based on the registration study, such as potential non-compliance with the clinical protocol.

Study locations

Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 China

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-02.